On October 3, 2024, Teva Pharmaceuticals and mAbxience, a Fresenius Kabi majority-owned group, announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar ...

Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess ® enterprise ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TEL AVIV, Israel, & MADRID--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority ...

On December 22, 2025, the FDA approved mAbxience and Amneal’s Biologics Licensing Applications (BLAs) for BONCRESA™ (denosumab-mobz) and OZILTUS™ (denosumab-mobz), biosimilars referencing Amgen’s ...

mAbxience secures its second 4,000L ABEC Custom Single Run (CSR®) bioreactor to increase manufacturing capacity at its Leon, Spain facility BETHLEHEM, Pa.--(BUSINESS WIRE)--ABEC, a global provider of ...

(RTTNews) - Abbott Laboratories (ABT) announced Wednesday an agreement with Spain-based global biotech firm mAbxience Holdings S.L. to commercialize several biosimilars focusing on oncology, women's ...

MADRID, Dec. 4, 2025 /PRNewswire/ -- mAbxience, a Fresenius entity, and HP Inc., a global leader in technology, announce a new project to develop an innovative artificial intelligence (AI) solution ...

mAbxience secures its second 4,000L ABEC Custom Single Run (CSR®) bioreactor to increase manufacturing capacity at its Leon, Spain facility In April 2022, and after being approved in Europe, Canada, ...

mAbxience, a Fresenius entity, and HP Inc., a global leader in technology, announce a new project to develop an innovative artificial intelligence (AI) solution that optimizes the production process ...